Alsharhan Hind, Ng Bobby G, Daniel Earnest James Paul, Friedman Jennifer, Pivnick Eniko K, Al-Hashem Amal, Faqeih Eissa Ali, Liu Pengfei, Engelhardt Nicole M, Keller Kierstin N, Chen Jie, Mazzeo Pamela A, Rosenfeld Jill A, Bamshad Michael J, Nickerson Deborah A, Raymond Kimiyo M, Freeze Hudson H, He Miao, Edmondson Andrew C, Lam Christina
Department of Pediatrics, Division of Human Genetics, Section of Metabolism, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
J Inherit Metab Dis. 2021 Jul;44(4):987-1000. doi: 10.1002/jimd.12367. Epub 2021 Mar 1.
Congenital disorders of glycosylation (CDGs) are a continuously expanding group of monogenic disorders of glycoprotein and glycolipid biosynthesis that cause multisystem diseases. Individuals with ALG3-CDG frequently exhibit severe neurological involvement (epilepsy, microcephaly, and hypotonia), ocular anomalies, dysmorphic features, skeletal anomalies, and feeding difficulties. We present 10 unreported individuals diagnosed with ALG3-CDG based on molecular and biochemical testing with 11 novel variants in ALG3, bringing the total to 40 reported individuals. In addition to the typical multisystem disease seen in ALG3-CDG, we expand the symptomatology of ALG3-CDG to now include endocrine abnormalities, neural tube defects, mild aortic root dilatation, immunodeficiency, and renal anomalies. N-glycan analyses of these individuals showed combined deficiencies of hybrid glycans and glycan extension beyond Man GlcNAc consistent with their truncated lipid-linked precursor oligosaccharides. This spectrum of N-glycan changes is unique to ALG3-CDG. These expanded features of ALG3-CDG facilitate diagnosis and suggest that optimal management should include baseline endocrine, renal, cardiac, and immunological evaluation at the time of diagnosis and with ongoing monitoring.
先天性糖基化障碍(CDG)是一组不断扩大的单基因糖蛋白和糖脂生物合成障碍疾病,可导致多系统疾病。患有ALG3-CDG的个体常表现出严重的神经系统受累(癫痫、小头畸形和肌张力减退)、眼部异常、畸形特征、骨骼异常和喂养困难。我们报告了10例通过分子和生化检测诊断为ALG3-CDG的未报道个体,其ALG3基因有11种新变异,使报道的个体总数达到40例。除了ALG3-CDG中常见的典型多系统疾病外,我们将ALG3-CDG的症状学扩展至现在包括内分泌异常、神经管缺陷、轻度主动脉根部扩张、免疫缺陷和肾脏异常。对这些个体的N-聚糖分析显示,杂合聚糖和超出Man GlcNAc的聚糖延伸存在联合缺陷,这与其截短的脂连接前体寡糖一致。这种N-聚糖变化谱是ALG3-CDG所特有的。ALG3-CDG这些扩展的特征有助于诊断,并表明最佳管理应包括在诊断时及持续监测时进行基线内分泌、肾脏、心脏和免疫学评估。